MARKET

ALXO

ALXO

Alx Oncology Holdings Inc
NASDAQ
1.135
+0.025
+2.25%
Opening 14:59 10/07 EDT
OPEN
1.100
PREV CLOSE
1.110
HIGH
1.150
LOW
1.100
VOLUME
413.36K
TURNOVER
--
52 WEEK HIGH
2.660
52 WEEK LOW
1.050
MARKET CAP
156.94M
P/E (TTM)
-0.9972
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALXO last week (0928-1002)?
Weekly Report · 2d ago
H.C. Wainwright Reaffirms Their Buy Rating on ALX Oncology Holdings (ALXO)
TipRanks · 6d ago
ALX Oncology announces publication of data from ASPEN-06 Phase 2 trial
TipRanks · 09/28 12:31
ALX Oncology Holdings Announces Publication Of Clinical Data From Its ASPEN-06 Randomized Phase 2 Clinical Trial In Nature Medicine, Showing Durable Clinical Benefit With Evorpacept In HER2-Positive Gastric Cancer
Benzinga · 09/28 12:03
Weekly Report: what happened at ALXO last week (0921-0925)?
Weekly Report · 09/28 09:47
H.C. Wainwright Sticks to Their Buy Rating for ALX Oncology Holdings (ALXO)
TipRanks · 09/21 17:55
Analysts Are Bullish on Top Healthcare Stocks: ALX Oncology Holdings (ALXO), Tonix Pharma (TNXP)
TipRanks · 09/21 14:01
Weekly Report: what happened at ALXO last week (0914-0918)?
Weekly Report · 09/21 09:47
More
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.

Webull offers ALX Oncology Holdings Inc stock information, including NASDAQ: ALXO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALXO stock methods without spending real money on the virtual paper trading platform.